Last reviewed · How we verify
Antiepileptic drug (AED)
Antiepileptic drugs reduce seizure activity by modulating neuronal excitability through various mechanisms including sodium channel blockade, GABA enhancement, or calcium channel inhibition.
Antiepileptic drugs reduce seizure activity by modulating neuronal excitability through various mechanisms including sodium channel blockade, GABA enhancement, or calcium channel inhibition. Used for Epilepsy (seizure prevention and management), Neuropathic pain (off-label for certain AEDs), Bipolar disorder (off-label for certain AEDs).
At a glance
| Generic name | Antiepileptic drug (AED) |
|---|---|
| Sponsor | Oslo University Hospital |
| Drug class | Antiepileptic drug (AED) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
AEDs comprise a diverse class of medications with multiple distinct mechanisms of action. Common mechanisms include blocking voltage-gated sodium channels to reduce neuronal firing, enhancing GABAergic inhibitory neurotransmission, modulating calcium channels, or affecting other neurotransmitter systems. The specific mechanism depends on the individual AED compound.
Approved indications
- Epilepsy (seizure prevention and management)
- Neuropathic pain (off-label for certain AEDs)
- Bipolar disorder (off-label for certain AEDs)
Common side effects
- Dizziness
- Drowsiness/Sedation
- Ataxia
- Nausea
- Diplopia
- Rash
Key clinical trials
- Seizure Treatment in Glioma (PHASE4)
- A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures (PHASE2)
- To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE) (PHASE3)
- Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures (PHASE3)
- Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures (PHASE2)
- A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)
- Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension (PHASE3)
- Inflammatory Biomarkers in Seizure
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antiepileptic drug (AED) CI brief — competitive landscape report
- Antiepileptic drug (AED) updates RSS · CI watch RSS
- Oslo University Hospital portfolio CI